Radiopharmaceuticals and nanoparticles used to kill cancer cells
Researchers have developed a potential cancer treatment using light from radiopharmaceuticals and polymer nanoparticles to kill cancer cells.
List view / Grid view
Researchers have developed a potential cancer treatment using light from radiopharmaceuticals and polymer nanoparticles to kill cancer cells.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
Researchers have created an X-ray scanning machine that shows the shape of an object and its molecular composition.
Dr Jo Brewer outlines research into allogeneic products by gene editing stem cells, which has the potential to build a broad family of multiple immune cell types, including T-cell therapies.
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Scientists have discovered that hepatic stellate cells are key in allowing dormant cancer cells to awaken and form fatal metastases.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.